• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Nanoviricides Inc (NY: NNVC )

    1.890 +0.060 (+3.28%)
    Official Closing Price Updated: 8:00 PM EDT, May 10, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 192,660
    Open 1.570
    Bid (Size) 1.810 (1)
    Ask (Size) 1.920 (16)
    Prev. Close 1.830
    Today's Range 1.560 - 1.900
    52wk Range 1.000 - 2.130
    Shares Outstanding 11,779,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City
    Via ACCESSWIRE
    A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
    Via ACCESSWIRE

    Performance

    YTD
    +83.50%
    +83.50%
    1 Month
    +44.27%
    +44.27%
    3 Month
    +65.79%
    +65.79%
    6 Month
    +78.30%
    +78.30%
    1 Year
    +54.92%
    +54.92%

    More News

    Read More
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    A Novel Broad-Spectrum Antiviral with Activity Against Influenza A
    Via ACCESSWIRE
    3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire
    Via InvestorPlace
    NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
    Via ACCESSWIRE
    NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
    Via ACCESSWIRE
    Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
    Via ACCESSWIRE
    A New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?
    Via Benzinga
    Exposures COVID-19
    Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
    Via ACCESSWIRE
    NanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase™ 2024
    Via Benzinga
    NanoViricides to Present at the Biotech Showcase in San Fransisco
    Via ACCESSWIRE
    Is This Ticker That InvestorsObserver Expects To Soar By More Than 350% Next Year On Your Watchlist?
    Via News Direct
    Topics Death
    Exposures COVID-19 Death
    The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
    Via ACCESSWIRE
    NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
    Via ACCESSWIRE
    Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
    Via ACCESSWIRE
    NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
    Via ACCESSWIRE
    NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
    Via ACCESSWIRE
    Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
    Via Benzinga
    Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
    Via ACCESSWIRE
    SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Why Are NanoViricides Shares Gaining Today
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.